Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CG Oncology, Inc. - Common stock (NQ:CGON)

53.27 -0.28 (-0.53%)
Streaming Delayed Price Updated: 3:07 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CG Oncology, Inc. - Common stock

< Previous 1 2 3 4 Next >
News headline image
Why CG Oncology (CGON) Stock Is Down 9% ↗
CG Oncology shares are trading lower by 9.2% during Wednesday's session. The company announced it filed an underwritten public offering of 7.3 million shares of its common stock. 
Via Benzinga
News headline image
Nasdaq Jumps 300 Points To Record Highs ↗
Stocks are higher this afternoon, after this morning's highly-anticipated CPI report met expectations. 
Via Talk Markets
Topics Stocks / Equities
News headline image
CG Oncology Announces Proposed Public Offering
From CG Oncology Inc.
Via GlobeNewswire
News headline image
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Demystifying CG Oncology: Insights From 7 Analyst Reviews ↗
 
Via Benzinga
News headline image
CG Oncology Touts Encouraging Data From Late-Stage Study Of Bladder Cancer Candidate ↗
CG Oncology's BOND-003 trial reveals durable efficacy of cretostimogene in NMIBC patients, with median DOR exceeding 27 months and no severe side effects. 
Via Benzinga
News headline image
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
From CG Oncology Inc.
Via GlobeNewswire
News headline image
A Closer Look at 9 Analyst Recommendations For CG Oncology ↗
 
Via Benzinga
News headline image
Decoding 10 Analyst Evaluations For CG Oncology ↗
 
Via Benzinga
News headline image
CG Oncology to Present Results on Cretostimogene Grenadenorepvec at the Society of Urologic Oncology (SUO) 25th Annual Meeting
Includes Late-Breaking Abstract on Results of Phase 3 BOND-003 Trial of Cretostimogene Monotherapy in High-Risk BCG-Unresponsive NMIBC and Four Trials in Progress Posters 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Reports Third Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Announces Nature Medicine Publication of Phase 1b Study Results Evaluating Cretostimogene Grenadenorepvec in Combination with Nivolumab in Muscle-Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise. 
Via MarketBeat
Topics Initial Public Offering
News headline image
This Sempra Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CGON Stock Earnings: CG Oncology Beats EPS for Q2 2024 ↗
CGON stock results show that CG Oncology beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
- First Patient Dosed in Expanded Access Program and Enrollment Ongoing - 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting
54% complete response (CR) rate at 24-month landmark and meets primary endpoint of the phase 2 study 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CGON Stock Earnings: CG Oncology Misses EPS for Q1 2024 ↗
CGON stock results show that CG Oncology missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
CG Oncology Reports First Quarter 2024 Financial Results and Provides Business Updates
From CG Oncology Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
From CG Oncology Inc.
Via GlobeNewswire
News headline image
Amgen Posts Upbeat Results, Joins OneSpan, Paylocity Holding, MercadoLibre And Other Big Stocks Moving Higher On Friday ↗
 
Via Benzinga
News headline image
CG Oncology to Host Virtual Investor Event on Friday, May 3, 2024
Company to host virtual investor event on Friday, May 3, 2024, at 4:30pm EDT following presentation of results from the Phase 3 BOND-003 trial at the 2024 AUA Annual Meeting 
From CG Oncology Inc.
Via GlobeNewswire
News headline image
CG Oncology to Unveil Encouraging Results on Cretostimogene in Combination with Pembrolizumab at ASCO 2024
- Final results of CORE-001 Phase 2 trial of cretostimogene in combination with pembrolizumab for the treatment of BCG-unresponsive NMIBC - 
From CG Oncology Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.